Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin‐secreting and clinically non‐functioning pituitary adenomas: predictive value of pituitary scintigraphy with <sup>123</sup>I‐methoxybenzamide

Colao, Annamaria; Ferone, Diego; Lastoria, Secondo; Cerbone, Gaetana; Sarno, Antonella Di; Somma, Carolina Di; Lucci, Rosa; Lombardi, Gaetano

doi:10.1046/j.1365-2265.2000.00951.x

Cited by 53 publications

(46 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, bromocriptine therapy has not been advocated on a routine basis. Better, but still variable, results have been reported on the treatment with the nonergot DA agonist quinagolide and the specific DA agonist cabergoline (20,23,26,27,34,35,39). The heterogeneity of responses to treatment has been attributed to the different pattern and level of expression of dopamine receptor subtypes in the individual tumors, as well as to possible alterations in the receptor-related signal transduction pathway (10,27,38).…”

Section: Discussionmentioning

confidence: 95%

“…We have previously demonstrated the superiority of 123 Iepidepride over 123 I-IBZM (31). In a series of ten patients with NFPA, the clinical usefulness of 123 I-IBZM scintigraphy for predicting tumor response to DA agonists could be demonstrated in two with high tumor uptake of the radioligand (34). Therefore, we studied the correlation between in vivo imaging of D2 receptors using 123 Iepidepride and the response of NFPA to long-term DA agonist therapy, as evaluated by magnetic resonance imaging (MRI).…”

Section: Introductionmentioning

confidence: 99%

“…The more prominent response was attained in patients whose tumors expressed the dopamine 2 receptor (D2R) short isoform (27). Several groups, including our own, have shown that D2-receptor imaging in pituitary adenomas is possible with single-photon emission computed tomography (SPECT) using (28)(29)(30)(31)(32)(33)(34)(35). We have previously demonstrated the superiority of 123 Iepidepride over 123 I-IBZM (31).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?

Herder¹,

Reijs²,

Feelders³

et al. 2006

eur j endocrinol

View full text Add to dashboard Cite

Objective: Clinically non-functioning pituitary adenomas (NFPAs) can express functional dopamine D2 receptors. Therapy with dopamine (DA) agonists may result in a NFPA size reduction. However, DA agonist-sensitive and -resistant NFPAs are clinically indistinguishable. We have studied the correlation between in vivo imaging of D2 receptors using 123 I-epidepride and the radiological response of NFPA to DA in 18 patients. Methods: Patients were treated with either cabergoline (1-2 mg/week) or quinagolide (150-300 mg/day) for a mean period of 89.7 months (range, 34-187 months). Results: Pituitary uptake of 123 I-epidepride varied from slight uptake classified as grade 0 to very high classified as grade 3. Grade 0 uptake was found in four patients; grade 1 in three; grade 2 in ten, and grade 3 in one. NFPA stabilization or shrinkage with DA agonist therapy showed no significant difference between grade 0, 1, and 2 tumors (mean tumor stabilization or shrinkage: 31, 30, and 36% respectively). However, when we considered a decrease in tumor size ranging from 0 to 20% as tumor stabilization and O20% decrease in tumor size as true shrinkage, one out of four NFPAs with grade 1 uptake, two out of three with grade 1 uptake, and eight out of ten with grade 2 uptake showed tumor shrinkage. Conclusion: In conclusion, there is limited clinical usefulness of dopamine D2 receptor imaging for predicting the clinical efficacy of DA agonist in selected patients with NFPAs. DA agonist therapy in NFPAs can result in tumor stabilization and shrinkage.European Journal of Endocrinology 155 717-723

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?

Herder¹,

Reijs²,

Feelders³

et al. 2006

eur j endocrinol

View full text Add to dashboard Cite

show abstract

“…Therapeutic trials may be performed in cases of recurring adenomas or when surgery is contraindicated. In vivo scintigraphy using D2 agonists (25,26), or in vitro D2 receptor studies in recurring tumors may allow a better selectivity in the therapeutic choice.…”

Section: Discussionmentioning

confidence: 99%

ACTH silent adenoma shrinking under cabergoline

Pétrossians

Ronci

Socin

et al. 2001

European Journal of Endocrinology

View full text Add to dashboard Cite

Objectives: The authors present a case report that proposes the use of cabergoline treatment in silent ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically nonfunctioning pituitary adenomas. Design: Following the clinical and radiological improvement of a recurrent silent ACTH adenoma in a 77-year-old patient treated with cabergoline (0.5 mg every 2 days for 2 years), in vitro studies of the original tumor were performed. Methods: The original tumor from the patient was studied by in situ hybridization and dopamine D2 receptor autoradiography. It was compared with four macroprolactinomas and two macroadenomas from patients with Cushing's disease. Results: The D2 receptor mRNA signal of the reported case was intense and of the same order of magnitude as that observed in control prolactinomas. Dopamine D2 receptor autoradiography was twice that of control corticotroph adenomas and was close to that observed in prolactinomas. Conclusions: This is the first description of an in vivo shrinkage of an ACTH silent adenoma under cabergoline. We demonstrate in vitro, the presence of D2 receptors in the primitive tumor in concentrations similar to those found in control prolactinomas. These results suggest that therapeutic trials with cabergoline might be undertaken in recurring cases of ACTH silent tumors and more generally, non-functioning pituitary adenomas.

show abstract

“…3/day and 0.5 mg/day respectively, had been employed. Recent studies on patients with NFA treated with somatostatin analogues have shown a rapid improvement of the visual field in most cases (56,57).…”

Section: Non-functioning Pituitary Adenomasmentioning

confidence: 99%

Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours

Colao

Filippella²,

Pivonello

et al. 2007

eur j endocrinol

Self Cite

View full text Add to dashboard Cite

Pituitary tumours express both somatostatin and dopamine receptors. Medical treatment with somatostatin analogues is a cornerstone of GH-and TSH-secreting tumours, while treatment with dopamine agonists is a cornerstone of prolactin-secreting tumours. Dopamine agonists have also demonstrated some efficacy in patients with GH-and TSH-secreting adenomas. Neither ACTHsecreting nor clinically non-functioning tumours have a well-established medical treatment. Nevertheless, some recent results have indicated a potential usefulness of the dopamine agonist cabergoline in patients with pituitary-dependent Cushing's disease. Combination treatment with both somatostatin analogues and dopamine agonists has been poorly investigated. Some studies conducted in small series have documented an additive effect of both drugs in patients with GH-secreting adenomas. Of mention is that none of the studies were randomised and cross-sectional so that the results should be confirmed by other well-designed studies. No data are available in other pituitary tumour histotypes. Preliminary observations in patients with clinically non-functioning adenomas are very promising.

show abstract

Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin‐secreting and clinically non‐functioning pituitary adenomas: predictive value of pituitary scintigraphy with ¹²³I‐methoxybenzamide

Cited by 53 publications

References 46 publications

Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?

Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?

ACTH silent adenoma shrinking under cabergoline

Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours

Contact Info

Product

Resources

About

Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin‐secreting and clinically non‐functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I‐methoxybenzamide

Cited by 53 publications

References 46 publications

Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?

Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?

ACTH silent adenoma shrinking under cabergoline

Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours

Contact Info

Product

Resources

About

Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin‐secreting and clinically non‐functioning pituitary adenomas: predictive value of pituitary scintigraphy with ¹²³I‐methoxybenzamide